Subjects with MSI-H pancreatic cancer who have not previously received pembrolizumab. advanced pancreatic cancer PHASE IB: No prior treatment with erlotinib is allowed for pancreatic cancer patients Histological or cytological proof of pancreatic adenocarcinoma; must have locally advanced or metastatic pancreatic cancer and received at least one dose of chemotherapy (any treatment line) and may have responding, stable or progressive disease Any prior treatment for pancreatic cancer Cystic pancreatic cancer; microcystic disease may be eligible First line treatment for metastatic pancreatic cancer. Have endocrine pancreatic tumors or ampullary cancer. PRE-SCREENING: Patients with advanced metastatic pancreatic cancer who have measurable disease Acute or chronic pancreatic disease within the last year prior to enrollment Any known active cancer other than pancreatic primary For LY + merestinib in pancreatic cancer: No previous therapy for pancreatic cancer Have received any type of cancer immunotherapy including the same pancreatic cancer vaccine Have received any anti-pancreatic cancer therapy (symptomatic therapies are allowed) ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Radiographic evidence of pancreatic cancer recurrence Prior surgical resection of pancreatic cancer Previous treatment for pancreatic cancer Locally advanced or metastatic pancreatic cancer for the pancreatic cancer cohort Progression or refractory disease to at least one regimen of therapy for metastatic disease in the breast and pancreatic cancer cohorts Metastatic pancreatic cancer Histologically or cytologically confirmed carcinoma of exocrine pancreatic head amenable to oncological surgical resection per findings on a pancreatic-specific computed tomography (CT) scan/MRI scan; tumors of the body that allow a surgical approach similar to pancreatic head tumors are acceptable Patients deemed as resectable by pancreatic protocol CT or MRI Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers Radiographic evidence of pancreatic cancer recurrence Endocrine or acinar pancreatic carcinoma Resectable pancreatic cancer Metastatic pancreatic cancer based on imaging Prior surgical or medical treatment for pancreatic cancer Pancreatic cancer cohort specific criteria:\r\n* Patients must have unresectable or metastatic pancreatic cancer\r\n* Patients must have failed at least one prior line of therapy for metastatic or unresectable disease or have recurred within months of completing adjuvant chemotherapy\r\n* Patients with liver metastases must have < % involvement of the liver Received any systemic treatment for pancreatic cancer =< days prior to first dose of rucaparib Advanced metastatic, progressing carcinoid or pancreatic islet cell cancers Acute or chronic pancreatic disease No definitive resection of pancreatic cancer Histological or cytological proof of pancreatic adenocarcinoma; must have locally advanced or metastatic pancreatic cancer who have received at least first line chemotherapy and may have responding, stable or progressive disease Have stable metastatic pancreatic cancer after receiving - doses of FOLFIRINOX (measurable disease is not required) Pancreatic Cancer Pancreatic Cancer Subjects with one or more prior treatments for their pancreatic cancer. Diarrhea, grade or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version [v.] .); pancreatic cancer patients with clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme replacement Subjects who have had radiotherapy for pancreatic cancer Acute or chronic pancreatic disease Resectable pancreatic cancer Willing and able to provide written informed consent: voluntary agreement to participate in the study following disclosure of risks and procedures required, including possibility of onset of exocrine pancreatic insufficiency with subsequent requirement for life-long pancreatic enzyme replacement Maldigestion/malabsorption syndrome pre-dating the diagnosis of pancreatic cancer. Acute or chronic pancreatic disease No prior treatment for pancreatic cancer Rare pancreatic neuroendocrine cancers such as, insulinomas, glucagonomas, gastrinomas. Adequate pancreatic function Endocrine or acinar pancreatic carcinoma Acute or chronic pancreatic disease No previous therapy for pancreatic cancer Diarrhea, grade or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version [v.] .); pancreatic cancer patients with clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme replacement Metastatic Pancreatic Cancer Acute or chronic pancreatic disease Normal pancreatic function Prior pancreatic surgery No use of H antagonist or pancreatic enzymes within hours before the first dose of alisertib. Pancreatic cancer of any type, biopsy-proven A diagnosis of pancreatic or other periampullary cancer is suspected preoperatively Known benign or indolent disease, including benign pancreatic cystic tumors or pancreatic endocrine tumors Undergoing pancreatic resection Malignant pancreatic disease mesothelioma, pancreatic cancer: - prior treatments Neuroendocrine or acinar pancreatic carcinoma Observational Arm only: patients with a pathological or clinical diagnosis of pancreatic cancer and beginning or continuing FOLFIRINOX chemotherapy Minocycline trial only: patients who have had prior treatment for pancreatic cancer within the past six months may be excluded at the discretion of the investigator Patients with prior pancreatic surgery or cancers One of the following high-risk groups\r\n* Patients will be eligible if they have or more relatives with pancreatic cancer and have a first degree relationship with at least one of the relatives with pancreatic cancer\r\n** If only family members are affected then both must have had pancreatic cancer and a first-degree relationship with individual screened\r\n** If there are more than affected individuals on the same side of the family at least one of the individuals must have a first-degree relationship with the member being screened\r\n** Patients at least years (yrs) old or yrs younger than the youngest affected individual\r\n* Peutz-Jeghers syndrome (PJS) patients age > \r\n* Hereditary pancreatitis patients\r\n* Patients with familial atypical multiple mole melanoma syndrome (FAMMM)\r\n* Patients with BRCA mutation and at least one first or second degree relative with documented pancreatic cancer Pancreatic insufficiency or disease Pancreatic carcinoma: Determined unresectable by a pancreatic cancer surgeon or a multi-disciplinary or gastrointestinal oncology Tumor Board Patients who have received chemotherapy for pancreatic cancer, other than up to cycles of mFOLFIRINOX as noted above GROUPS , , AND : Group : participants identified as being high-risk for familial or hereditary pancreatic cancer, and must conform to one or more of the following requirements:\r\n* Have a strong family history of pancreatic cancer; this is defined as pancreatic cancer occurring in one first- degree relative and two other relatives, or two first- degree relatives; or, \r\n* Have a known high-risk genetic syndrome (e.g., BRCA &, STK, CDNKA, PRSS, and MSH &) HEALTHY VOLUNTEERS (Group ): Group participants must have no history of cancer, pancreatic disease, or family history of pancreatic cancer\r\n* Family history will be defined as pancreatic cancer occurring in one first-degree relative and two other relatives, or two first-degree relatives Undergoing pancreatic cancer resection PANCREATIC CANCER PATIENT INCLUSION CRITERIA: PANCREATIC CANCER PATIENT EXCLUSION CRITERIA: Patients who will undergo curative pancreatectomy for pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, or pancreatic cysts (malignant or benign) (PCS study)